ArticleThe Laryngoscope2025
Feasibility of Treating Eosinophilic Chronic Rhinosinusitis Using Short-Chain Fatty Acids.
Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Baicalein mitigates epithelial barrier impairment and microbiota dysbiosis in allergic asthmatic mice via the gut‑lung axis.Chinese medicine · 2026Article
- Beyond dysbiosis: microbial metabolites as key remodelers of nasal mucosal immune tolerance in chronic rhinosinusitis.Frontiers in immunology · 2026Review
- Immune-inflammatory endotypes of chronic rhinosinusitis: from epithelial alarmins to personalized therapy.Frontiers in immunology · 2026Review
- Feasibility of Treating Eosinophilic Chronic Rhinosinusitis Using Short-Chain Fatty Acids.The Laryngoscope · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEpithelial cell-derived cytokines play a key role in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNPs). Short-chain fatty acids (SCFAs) are carboxylic acids with 1-6 carbon atoms that are produced by the microbiota, which play a significant role in inflammation. We evaluated the potential role of SCFAs in eosinophilic chronic rhinosinusitis (ECRS).
methodsGene expression levels of G protein-coupled receptor 41/free fatty acid receptor 3 (GPR41/FFAR3), GPR43/FFAR2, thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33 in nasal polyp (NP) tissues were analyzed using quantitative real-time polymerase chain reaction. Primary normal human bronchial epithelial (NHBE) cells were stimulated with polyinosinic-polycytidylic acid (poly(I:C)) in the presence or absence of SCFAs, and TSLP levels were measured. Immunohistochemical analysis was conducted to evaluate GPR41 expression in eosinophils and the Eol-1 human eosinophilic leukemic cell line (Eol-1 cells). The viability of Eol-1 cells treated with propionic acid was also assessed.
resultsBoth GPR41 and GPR43 mRNA expression was significantly higher in ECRS-NPs than in non-ECRS-NPs. The level of TSLP mRNA expression was also significantly elevated in ECRS-NPs that correlated with eosinophil counts in NP tissues. Although poly(I:C) stimulation induced TSLP expression in NHBE cells, acetic acid, propionic acid, and butyric acid significantly suppressed TSLP expression in a concentration-dependent manner. GPR43 was expressed in eosinophils from NP tissues and Eol-1 cells. 1 mM propionic acid significantly suppressed Eol-1 cell survival.
conclusionsSCFAs, particularly propionic acid, may be effective in treating ECRS by suppressing TSLP expression and eosinophils. LEVEL OF EVIDENCE: NA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.